Our Story
When the founder of ConceptoMed, M.D. Christian Mide, performed arthrocentesis procedures, with repeated disconnections of the syringe from a firmly attached needle placed inside a knee, he felt the need for a “crowbar” to ease the disconnection, improve aseptic safety and reduce patient pain.
The medical need quickly emerged into a potential product idea and became the base for the LuerJack technology and the foundation of ConceptoMed.
Today ConceptoMed consists of a team of innovative and dedicated professionals with strong educational background and international experience located at our headquarters at Ballstad in the beautiful Lofoten Islands, Norway. We create smart medtech systems that empower smart healthcare professionals and improve patient care. So far we have launched two medical device product groups with global potential from our strong pipeline.
Key Company Milestones
ConceptoMed was founded
Substantial development and design work in collaboration with K8 Industridesign
First patent granted for LuerJack
The Intervention Centre at Oslo University Hospital issued a positive evaluation report of LuerJack
Signed first distribution agreement for LuerJack
Received European approval (CE Mark) for the LuerJack syringe
International sales and market department established in Oslo
Branch office established in Oslo, Norway
Major equity round in an oversubscribed private placement of NOK 100 Million
First patent granted for LuerJack Lock
Branch office established in Jönköping, Sweden
First US patent issued for LuerJack
ConceptoMed named a global ‘Disrupt 100’ company
ConceptoMed receives ISO13485 certification
European and Australian patent granted for LuerJack
ConceptoMed named “Company of the year 2016” by Norway Healthtech
FDA 510(k) clearance for first LuerJack Slip
Granted patents for LuerJack in Japan
Granted patent for LuerJack in China, Hong Kong, Singapore, Mexico
FDA 510(k) clearance for LuerJack Slip and Lock
Limited market release of LuerJack in soft blister in Europe
Automated manufacturing under installation in Sweden
Several granted patents, incl. US patent for technology covering screw-fit fluid connections with one-handed disconnection
Relocated all resources to Ballstad HQ
Heavy development work building on existing and expanding IP portfolio
Actively searching for a global partnering opportunity
ConceptoMed was founded
Substantial development and design work in collaboration with K8 Industridesign
First patent granted for LuerJack
The Intervention Centre at Oslo University Hospital issued a positive evaluation report of LuerJack
Signed first distribution agreement for LuerJack
Received European approval (CE Mark) for the LuerJack syringe
International sales and market department established in Oslo
Branch office established in Oslo, Norway
Major equity round in an oversubscribed private placement of NOK 100 Million
First patent granted for LuerJack Lock
Branch office established in Jönköping, Sweden
First US patent issued for LuerJack
ConceptoMed named a global ‘Disrupt 100’ company
ConceptoMed receives ISO13485 certification
European and Australian patent granted for LuerJack
ConceptoMed named “Company of the year 2016” by Norway Healthtech
FDA 510(k) clearance for first LuerJack Slip
Granted patents for LuerJack in Japan
Granted patent for LuerJack in China, Hong Kong, Singapore, Mexico
FDA 510(k) clearance for LuerJack Slip and Lock
Limited market release of LuerJack in soft blister in Europe
Automated manufacturing under installation in Sweden
Several granted patents, incl. US patent for technology covering screw-fit fluid connections with one-handed disconnection
Relocated all resources to Ballstad HQ
Heavy development work building on existing and expanding IP portfolio
Actively searching for a global partnering opportunity
